Pneumocystis Infection - Pipeline Review, H1 2015

01:13 EDT 15 Apr 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Pneumocystis Infection - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-03-10. This 29-page report is available in PDF from $2000.

Pneumocystis Infection - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Pneumocystis Infection - Pipeline Review, H1 2015’, provides an overview of the Pneumocystis Infection’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pneumocystis Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pneumocystis Infection and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Pneumocystis Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pneumocystis Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pneumocystis Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pneumocystis Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Pneumocystis Infection Overview 5
Therapeutics Development 6
Pipeline Products for Pneumocystis Infection - Overview 6
Pipeline Products for Pneumocystis Infection - Comparative Analysis 7
Pneumocystis Infection - Therapeutics under Development by Companies 8
Pneumocystis Infection - Therapeutics under Investigation by Universities/Institutes 9
Pneumocystis Infection - Pipeline Products Glance 10
Early Stage Products 10
Pneumocystis Infection - Products under Development by Companies 11
Pneumocystis Infection - Products under Investigation by Universities/Institutes 12
Pneumocystis Infection - Companies Involved in Therapeutics Development 13
BioDiem Ltd 13
Pneumocystis Infection - Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Route of Administration 15
Assessment by Molecule Type 16
Drug Profiles 18
BDM-I - Drug Profile 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Monoclonal Antibody for Pneumocystis Infection - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
MVX-504 - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
MVX-505 - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
pneumocystis vaccine - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Pneumocystis Infection - Recent Pipeline Updates 24
Pneumocystis Infection - Discontinued Products 26
Pneumocystis Infection - Product Development Milestones 27
Featured News & Press Releases 27
May 10, 2013: BioDiem's BDM-I Progresses To Preclinical Animal Studies In NIH Research Program As Fungal Infection Treatment 27
Jun 04, 2012: MiniVax’s Pneumocystis Vaccine Candidate Induces Significant anti-Pneumocystis Antibody Responses and Reduced Fungal Load 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 28
Disclaimer 29

For more information open Pneumocystis Infection - Pipeline Review, H1 2015.


Original Article: Pneumocystis Infection - Pipeline Review, H1 2015


More From BioPortfolio on "Pneumocystis Infection - Pipeline Review, H1 2015"

Quick Search


Relevant Topics

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...